SecSonar.com

Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Phathom Pharmaceuticals, Inc. (PHAT) is a Biotechnology company based in US with a market capitalization of $788.3M. Revenue grew 216.9% year-over-year and free cash flow was negative at -$167M. This page tracks PHAT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 427 employees · IPO Oct 25, 2019

Valuation

Valuation & price

$11.87 · as of May 17, 2026 · -34.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$17.87$12.85$7.83Jul 25Dec 25Jul 26Jul 7, 25$8.66Jul 9, 25$9.37Jul 11, 25$9.18Jul 15, 25$8.54Jul 17, 25$8.32Jul 21, 25$7.83Jul 23, 25$8.57Jul 25, 25$9.63Jul 29, 25$8.62Jul 31, 25$8.54Aug 4, 25$8.64Aug 6, 25$8.68Aug 11, 25$10.28Aug 13, 25$10.48Aug 15, 25$10.24Aug 19, 25$10.38Aug 21, 25$10.95Aug 25, 25$11.57Aug 27, 25$12.44Aug 29, 25$12.18Sep 3, 25$11.88Sep 5, 25$12.34Sep 9, 25$12.89Sep 11, 25$12.06Sep 16, 25$10.98Sep 18, 25$11.75Sep 22, 25$11.74Sep 24, 25$11.71Sep 26, 25$11.78Sep 30, 25$11.77Oct 2, 25$11.82Oct 6, 25$11.61Oct 8, 25$11.05Oct 10, 25$11.82Oct 14, 25$12.50Oct 16, 25$13.31Oct 21, 25$14.00Oct 23, 25$13.61Oct 27, 25$13.81Oct 29, 25$13.53Oct 31, 25$13.55Nov 4, 25$13.49Nov 6, 25$13.04Nov 10, 25$13.73Nov 12, 25$14.62Nov 14, 25$14.56Nov 18, 25$15.00Nov 20, 25$14.36Nov 25, 25$14.93Nov 28, 25$15.62Dec 2, 25$14.74Dec 4, 25$14.70Dec 8, 25$14.90Dec 10, 25$14.55Dec 12, 25$14.56Dec 16, 25$15.24Dec 18, 25$16.28Dec 22, 25$17.87Dec 24, 25$17.66Dec 29, 25$17.22Jan 2, 26$15.71Jan 6, 26$16.37Jan 8, 26$15.60Jan 12, 26$14.47Jan 14, 26$15.14Jan 16, 26$14.06Jan 21, 26$13.61Jan 23, 26$13.50Jan 27, 26$14.23Jan 29, 26$13.53Feb 2, 26$13.81Feb 4, 26$13.23Feb 9, 26$12.78Feb 11, 26$12.23Feb 13, 26$12.02Feb 18, 26$11.88Feb 20, 26$11.42Feb 24, 26$11.61Feb 26, 26$13.56Mar 2, 26$11.46Mar 4, 26$11.06Mar 6, 26$10.67Mar 10, 26$11.11Mar 12, 26$10.22Mar 17, 26$10.85Mar 19, 26$11.15Mar 23, 26$10.57Mar 25, 26$10.47Mar 27, 26$10.58Mar 31, 26$11.11Apr 2, 26$11.34Apr 7, 26$11.55Apr 9, 26$12.64Apr 13, 26$12.67Apr 15, 26$12.79Apr 17, 26$13.19Apr 22, 26$11.73Apr 24, 26$11.70Apr 28, 26$11.33Apr 30, 26$11.20May 4, 26$12.87May 6, 26$12.67May 8, 26$12.16May 12, 26$12.53May 14, 26$13.05May 18, 26$11.39May 20, 26$11.87May 22, 26$11.33May 28, 26$10.32Jun 1, 26$9.24Jun 3, 26$10.09Jun 5, 26$10.13Jun 9, 26$9.82Jun 11, 26$10.27Jun 15, 26$10.71Jun 17, 26$11.00Jun 22, 26$10.69Jun 24, 26$10.61Jun 26, 26$10.72Jul 2, 26$11.20
$7.8352-week range$18.08
Loading valuation history…

Fundamentals

Key fundamentals

$788.3M

Market cap

216.9%

Revenue growth (YoY)

87.1%

Gross margin

-$167M

Free cash flow (USD)

-$127.3M

Net debt

Net cash position

15.4%

Share dilution

0/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2018 → 2025

FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$0.00FY 2023$682.0KFY 2024$55.3MFY 2025$175.1M
$0$175.1M

Free cash flow by year

2018 → 2025

FY 2018$-1.0MFY 2019$-61.8MFY 2020$-70.7MFY 2021$-148.8MFY 2022$-147.6MFY 2023$-139.2MFY 2024$-266.9MFY 2025$-167.0M
-$1M-$167M

Gross margin by year

2023 → 2025

FY 202375.5%FY 202485.6%FY 202587.1%
75.5%87.1%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 30, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventClinical Trial Enrollment CompleteJun 23, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 21, 2026Filing
  • 8-K eventEarnings ReleaseApr 30, 2026Filing
  • Quarterly report10-Q FiledApr 30, 2026Filing

Questions

Frequently asked questions

What is Phathom Pharmaceuticals, Inc.'s market cap?

Phathom Pharmaceuticals, Inc. (PHAT) has a market capitalization of $788.3M.

What is PHAT's P/E ratio?

A meaningful P/E ratio is not available for PHAT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying PHAT stock?

SEC Form 4 filings show no open-market insider buys at Phathom Pharmaceuticals, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

GERN

Geron Corporation

$805.1M

ZBIO

Zenas BioPharma, Inc.

$829.2M

ETON

Eton Pharmaceuticals, Inc.

$834.6M

TBPH

Theravance Biopharma, Inc.

$835.7M

XNCR

Xencor, Inc.

$885.3M

ZVRA

Zevra Therapeutics, Inc.

$684.8M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.